

Rosaria Volpini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4935351/publications.pdf>

Version: 2024-02-01

81
papers

2,388
citations

186265

28
h-index

233421

45
g-index

81
all docs

81
docs citations

81
times ranked

2012
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. <i>Neuropharmacology</i> , 2021, 190, 108352.	4.1	386
2	N6-Alkyl-2-alkynyl Derivatives of Adenosine as Potent and Selective Agonists at the Human Adenosine A3 Receptor and a Starting Point for Searching A2B Ligands. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 3271-3279.	6.4	104
3	2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors. <i>Journal of Medicinal Chemistry</i> , 1992, 35, 2363-2368.	6.4	98
4	New substituted 9-alkylpurines as adenosine receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 1998, 6, 523-533.	3.0	82
5	Medicinal Chemistry and Pharmacology of A2B Adenosine Receptors. <i>Current Topics in Medicinal Chemistry</i> , 2003, 3, 427-443.	2.1	81
6	Synthesis and Biological Activity of a New Series of N6-Arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-Carboxamido Derivatives of Adenosine-5'-N-ethyluronamide as A1 and A3 Adenosine Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 3174-3185.	6.4	68
7	2-Alkynyl Derivatives of Adenosine-5'-N-ethyluronamide: Selective A2 Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 1720-1726.	6.4	67
8	2-Aralkynyl and 2-Heteroalkynyl Derivatives of Adenosine-5'-N-Ethyluronamide as Selective A2a Adenosine Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 1462-1472.	6.4	62
9	[3H]HEMADO a novel tritiated agonist selective for the human adenosine A3 receptor. <i>European Journal of Pharmacology</i> , 2007, 556, 14-18.	3.5	60
10	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 2812-2822.	3.0	53
11	Medicinal Chemistry of Adenosine A2A Receptor Agonists. <i>Current Topics in Medicinal Chemistry</i> , 2003, 3, 387-401.	2.1	47
12	New adenosine A2A receptor antagonists: Actions on Parkinson's disease models. <i>European Journal of Pharmacology</i> , 2005, 512, 157-164.	3.5	45
13	Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17. <i>Purinergic Signalling</i> , 2011, 7, 463-468.	2.2	45
14	N-Cycloalkyl Derivatives of Adenosine and 1-Deazaadenosine as Agonists and Partial Agonists of the A1 Adenosine Receptor. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 250-260.	6.4	44
15	A new ethyladenine antagonist of adenosine A2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug. <i>Neuropharmacology</i> , 2010, 58, 613-623.	4.1	44
16	Structure-Activity Relationships of Adenine and Deazaadenine Derivatives as Ligands for Adenine Receptors, a New Purinergic Receptor Family. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5974-5989.	6.4	43
17	Adenosine Receptor Modeling: What Does the A2A Crystal Structure Tell Us?. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 993-1018.	2.1	42
18	Purinergic P2X receptors: Structural models and analysis of ligand-target interaction. <i>European Journal of Medicinal Chemistry</i> , 2015, 89, 561-580.	5.5	41

#	ARTICLE	IF	CITATIONS
19	Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists. <i>Current Medicinal Chemistry</i> , 2015, 22, 915-928.	2.4	41
20	N6-Methoxy-2-alkynyladenosine Derivatives as Highly Potent and Selective Ligands at the Human A3 Adenosine Receptor. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1222-1230.	6.4	38
21	Evidence for the Existence of a Specific G-protein-Coupled Receptor Activated by Guanosine. <i>ChemMedChem</i> , 2011, 6, 1074-1080.	3.2	36
22	Characterization of potent ligands at human recombinant adenosine receptors. <i>Drug Development Research</i> , 1998, 45, 176-181.	2.9	34
23	Synthesis and Biological Evaluation of 2-Alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine Derivatives as Potent and Highly Selective Agonists for the Human Adenosine A3 Receptor. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7897-7900.	6.4	34
24	9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2003, 367, 629-634.	3.0	33
25	Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications. <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 943-963.	5.0	33
26	Adenosine A _{2A} Receptor Antagonists: New 8-Substituted 9-Ethyladenines as Tools for in vivo Rat Models of Parkinson's Disease. <i>ChemMedChem</i> , 2009, 4, 1010-1019.	3.2	32
27	Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates DOPA-induced rotational behavior in a rodent model of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2015, 134, 740-747.	3.9	31
28	The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A _{2A} Receptor Subtype. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5772-5790.	6.4	31
29	The G-protein-Coupled Receptor GPR17: Overview and Update. <i>ChemMedChem</i> , 2016, 11, 2567-2574.	3.2	28
30	Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists. <i>Cells</i> , 2020, 9, 1739.	4.1	27
31	Molecular modeling study on potent and selective adenosine A3 receptor agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 7923-7930.	3.0	25
32	Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia. <i>Journal of Neurochemistry</i> , 2019, 149, 211-230.	3.9	24
33	Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2015, 96, 105-121.	5.5	23
34	Regulation of adenosine A _{2A} receptor gene expression in a model of binge eating in the amygdaloid complex of female rats. <i>Journal of Psychopharmacology</i> , 2019, 33, 1550-1561.	4.0	23
35	Adenine-Based Acyclic Nucleotides as Novel P2X ₃ Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4596-4603.	6.4	22
36	Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor. <i>In Silico Pharmacology</i> , 2013, 1, 24.	3.3	22

#	ARTICLE	IF	CITATIONS
37	Novel potent and highly selective human A3 adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: Molecular docking analysis and pharmacological studies. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 401-410.	3.0	21
38	Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch. <i>Biochemical Pharmacology</i> , 2014, 87, 321-331.	4.4	19
39	1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure- α -affinity relationships and molecular modeling studies. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 9-21.	3.0	18
40	Purine and deazapurine nucleosides: synthetic approaches, molecular modelling and biological activity. <i>Il Farmaco</i> , 2003, 58, 193-204.	0.9	15
41	Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases. <i>Frontiers in Pharmacology</i> , 2018, 9, 212.	3.5	15
42	Non-Nucleoside Agonists of the Adenosine Receptors: An Overview. <i>Pharmaceuticals</i> , 2019, 12, 150.	3.8	15
43	Antioxidant-Conjugated 1,2,4-Triazolo[4,3- <i>a</i>]pyrazin-3-one Derivatives: Highly Potent and Selective Human A _{2A} Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8511-8531.	6.4	15
44	Synthesis of New Nucleosides by coupling of chloropurines with 2- and 3-deoxy derivatives of N-methyl-D-ribofuranuronamide. <i>Helvetica Chimica Acta</i> , 1998, 81, 145-152.	1.6	14
45	Synthesis and Biological Activity of Trisubstituted Adenines as A _{2A} Adenosine Receptor Antagonists. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2007, 26, 1443-1446.	1.1	14
46	In vitro antibacterial activity of different adenosine analogues. <i>Journal of Medical Microbiology</i> , 2012, 61, 525-528.	1.8	14
47	8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands. <i>European Journal of Medicinal Chemistry</i> , 2013, 70, 525-535.	5.5	14
48	Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2794-2808.	3.0	14
49	Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β -amyloid-induced neurotoxicity in SH-SY5Y cells. <i>Bioorganic Chemistry</i> , 2019, 87, 380-394.	4.1	14
50	The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis. <i>Cells</i> , 2020, 9, 1509.	4.1	13
51	Combined Therapy of A1AR Agonists and A2AAR Antagonists in Neuroinflammation. <i>Molecules</i> , 2021, 26, 1188.	3.8	13
52	New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile. <i>Purinergic Signalling</i> , 2007, 3, 339-346.	2.2	12
53	The Length and Flexibility of the α -Substituent of 9 α -Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A _{2A} Adenosine Receptor. <i>ChemMedChem</i> , 2016, 11, 1829-1839.	3.2	12
54	P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications. <i>Frontiers in Pharmacology</i> , 2021, 12, 653561.	3.5	12

#	ARTICLE	IF	CITATIONS
55	2- and 8-alkynyl-9-ethyladenines: Synthesis and biological activity at human and rat adenosine receptors. <i>Purinergic Signalling</i> , 2005, 1, 173-181.	2.2	11
56	New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases. <i>European Journal of Medicinal Chemistry</i> , 2018, 151, 199-213.	5.5	11
57	Anticancer activity study of A3 adenosine receptor agonists. <i>Life Sciences</i> , 2018, 205, 155-163.	4.3	11
58	2,3-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents. <i>Purinergic Signalling</i> , 2017, 13, 61-74.	2.2	10
59	Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 118, 200-207.	4.0	10
60	Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 563-569.	2.2	10
61	Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors. Ranging from Pan Ligands to Combined A1/A2B Partial Agonists. <i>Pharmaceuticals</i> , 2019, 12, 159.	3.8	9
62	GPR17 receptor modulators and their therapeutic implications: review of recent patents. <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 85-95.	5.0	9
63	Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2020, 201, 112478.	5.5	9
64	Approaches for designing and discovering purinergic drugs for gastrointestinal diseases. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 687-703.	5.0	9
65	A _{2A} Adenosine Receptor Antagonists and their Potential in Neurological Disorders. <i>Current Medicinal Chemistry</i> , 2022, 29, 4780-4795.	2.4	9
66	2-ClATP exerts anti-tumoural actions not mediated by P2 receptors in neuronal and glial cell lines. <i>Biochemical Pharmacology</i> , 2004, 67, 621-630.	4.4	8
67	New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A1 adenosine receptor antagonists. <i>Collection of Czechoslovak Chemical Communications</i> , 2011, 76, 1379-1393.	1.0	8
68	Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A _{2A} Adenosine Receptor. <i>Molecular Informatics</i> , 2016, 35, 403-413.	2.5	8
69	Investigation on 2,3-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 493-498.	2.8	8
70	Overview on Radiolabel-Free in vitro Assays for GPCRs. <i>Mini-Reviews in Medicinal Chemistry</i> , 2016, 17, 3-14.	2.4	5
71	A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?. <i>Molecules</i> , 2022, 27, 2386.	3.8	5
72	Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists. <i>European Journal of Medicinal Chemistry</i> , 2013, 65, 41-50.	5.5	4

#	ARTICLE	IF	CITATIONS
73	New A2A adenosine receptor antagonists: a structure-based upside-down interaction in the receptor cavity. <i>Bioorganic Chemistry</i> , 2019, 92, 103183.	4.1	4
74	New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127126.	2.2	4
75	Design and Synthesis of Novel Thiazolo[5,4-d]pyrimidine Derivatives with High Affinity for Both the Adenosine A1 and A2A Receptors, and Efficacy in Animal Models of Depression. <i>Pharmaceuticals</i> , 2021, 14, 657.	3.8	4
76	4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives. <i>Pharmaceuticals</i> , 2022, 15, 478.	3.8	4
77	New sensible method to quantize the intestinal absorption of receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 3328-3333.	3.0	2
78	A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity. <i>Pharmaceuticals</i> , 2022, 15, 164.	3.8	1
79	A patent review of adenosine A _{2B} receptor antagonists (2016-present). <i>Expert Opinion on Therapeutic Patents</i> , 2022, 32, 689-712.	5.0	1
80	Multipotent Stromal Cells from Subcutaneous Adipose Tissue of Normal Weight and Obese Subjects: Modulation of Their Adipogenic Differentiation by Adenosine A1 Receptor Ligands. <i>Cells</i> , 2021, 10, 3560.	4.1	1
81	Inside Cover: Evidence for the Existence of a Specific G-protein-Coupled Receptor Activated by Guanosine (ChemMedChem 6/2011). <i>ChemMedChem</i> , 2011, 6, 946-946.	3.2	0